- Home
- NBIX
as 06-20-2025 4:00pm EST
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 12.2B | IPO Year: | 1996 |
| Target Price: | $163.20 | AVG Volume (30 days): | 915.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.96 | EPS Growth: | -17.91 |
| 52 Week Low/High: | $84.23 - $157.98 | Next Earning Date: | 07-31-2025 |
| Revenue: | $2,412,600,000 | Revenue Growth: | 21.73% |
| Revenue Growth (this year): | 16.29% | Revenue Growth (next year): | 15.08% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | NBIX | Director | May 27 '25 | Sell | $120.38 | 9,613 | $1,157,211.02 | 514,596 | |
| RASTETTER WILLIAM H | NBIX | Director | May 5 '25 | Sell | $110.20 | 30,000 | $3,305,952.00 | 37,491 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 hours ago
Exploring 3 High Growth Tech Stocks In The US Market
PR Newswire
a day ago
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
Argus Research
11 days ago
NBIX: What does Argus have to say about NBIX?
MT Newswires
12 days ago
Neurocrine Biosciences Names Lewis Choi as Chief Information Officer
PR Newswire
12 days ago
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
Zacks
18 days ago
CPRX or NBIX: Which Is the Better Value Stock Right Now?
MT Newswires
19 days ago
Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says
PR Newswire
19 days ago
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
Compare NBIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.